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Abstract
Objective. The aim of this study was to describe dose regimens, dose escalation and clinical outcomes in
TNF-a inhibitor (TNFi)naive patients with PsA treated with infliximab in routine rheumatology care.
Methods. We conducted an observational cohort study based on the nationwide Danish Rheumatologic
Database (DANBIO) and Center for Rheumatology Research (ICEBIO) registries. Stratified by country,
characteristics of patients treated with 43 mg infliximab/kg body weight, 35 mg/kg or 55 mg/kg every
8 weeks were described. Outcomes were evaluated by ACR 20%, 50% and 70% (ACR20/50/70) re-
sponses and European League Against Rheumatism good response after 6 months, disease activity
after 12 months, KaplanMeier plots and regression analyses.
Results. Four hundred and sixty-two patients (376 Danish, 86 Icelandic) received treatment with infliximab.
In Danish patients, the starting dose was 43 mg/kg in 110 patients (29%), 35 mg/kg in 157 (42%), 55 mg/
kg in 38 (10%) and unregistered in 71 (19%). In Icelandic patients, corresponding numbers were 64 (74%),
17 (27%), 0 (0%) and 5 (6%). Patients with a higher body weight received lower doses per kilogram. Danish
patients received higher doses than Icelandic patients at baseline [median 3.1 (interquartile range 3.03.8) vs
2.3 (2.12.9) mg/kg, P< 0.05] and after 12 months [3.3 (3.04.5) vs 2.9 (2.23.5) mg/kg, P<0.0001]. After 12
months, 58% of Danish and 66% of Icelandic patients maintained treatment. Danish patients had shorter
drug survival than Icelandic patients (1183 vs 483 days). In univariate analyses stratified by country, time until
dose escalation, response rates, drug survival and 1-year’s disease activity were independent of starting
dose. Drug survival was shorter among patients not receiving concomitant MTX.
Conclusion. In clinical practice,> 70% of Icelandic and Danish PsA patients treated with infliximab
received sustained doses below the 5 mg/kg every 8 weeks recommended in international guidelines.
Lower starting doses did not affect drug survival or response.
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Introduction
Therapy with TNF-a inhibitors (TNFis) has improved treat-
ment outcome in patients with PsA who have failed treat-
ment with conventional synthetic DMARDs (csDMARDs)
[18]. B
By March 2013, four TNFis were marketed in Denmark
and Iceland to treat PsA: adalimumab, etanercept, goli-
mumab and infliximab [7, 912]. The recommended dose
regimens for adalimumab, etanercept and golimumab in
PsA are equal to the regimens in RA, i.e. fixed dosage
independent of the patient’s body weight. For infliximab,
patients with PsA are recommended higher doses than
patients with RA, i.e. 5 vs 3 mg/kg body weight every 8
weeks [1316]. This recommendation is based on data
from randomized placebo-controlled clinical trials [4, 6,
17, 18]. Data on the effectiveness of lower infliximab
doses in PsA are, however, scarce [1923].
The Danish nationwide DANBIO registry now includes
>10 years of prospective follow-up of patients with in-
flammatory arthritis treated with biologics in routine care
[24, 25]. Similarly, Icelandic patients have been registered
and followed in the ICEBIO registry since 2007 [26].
Based on data from DANBIO and ICEBIO we aimed to
describe the following: (i) the infliximab dose regimens
used in clinical practice, (ii) dose escalation and (iii)
whether the starting dose regimen affected (a) treatment
response and (b) drug survival in TNFi-naive patients with
PsA receiving their first infliximab treatment course.
Patients and methods
The nationwide Danish DANBIO registry commenced in
2000 and covers >90% of Danish adults treated with bio-
logics due to rheumatic disease in routine care [2729].
Prospective data registration in the Icelandic ICEBIO
registry started in 2007. Biologic treatment courses,
which were started in Iceland before 2007, have been
registered retrospectively. Currently ICEBIO covers
>95% of all biologic treatment given in Iceland in patients
with rheumatic disorders (B. Gudbjorsson, 2013, personal
communication). According to Danish legislation, the
registration and publication of data from clinical registries
does not require patient consent or approval by an ethics
committee. In Iceland, this study was approved by the
National Bioethics Committee (VSNb201310035/03.15)
and the Data Protection Authority (2012080907HGK).
In Iceland, local hospital guidelines in PsA recommend
infliximab doses of 200 mg every 8 weeks, irrespective of
the patient’s body weight. In cases of insufficient re-
sponse, doses are increased stepwise to 300, 400 or
500 mg [26, 30]. In Denmark, no national treatment guide-
lines existed during the study period.
By March 2013, 4966 patients with a diagnosis of PsA
according to the treating physician had been registered
(4742 patients in DANBIO, 224 in ICEBIO). Among these,
3237 patients were treated only with csDMARDs. The re-
maining 1729 patients were treated with biologic DMARDs
(bDMARDs): 462 patients received infliximab as the first
bDMARD, 705 adalimumab, 371 etanercept, 51
golimumab and 19 received other biologic drugs. We
excluded 82 patients treated with bDMARDs as part of
clinical trials and 39 patients with insufficient data on
their first TNFi treatment course. Only the 462 patients
who received infliximab as the first bDMARD were
included in the present study.
DANBIO and ICEBIO use a common web-based system
(www.danbio-online.dk) [31]. Baseline demographics in-
clude age, gender, body weight, height, disease duration,
previous or current treatment with MTX or other
csDMARDs. Functional status and peripheral disease ac-
tivity are monitored prospectively by the Health HAQ [32],
the 28-joint DAS (DAS28) [33], CRP level (normal range
410 mg/l) and visual analogue scales (VASs) for pain, pa-
tient’s global assessment and fatigue. It is not explicitly
registered whether a patient has spinal disease. Data
registration is recommended to occur at least biannually,
or when the medical treatment is changed [24].
Infliximab dose regimens
The infliximab dose per infusion was reported as (i) the
total dose per infusion (in mg) and (ii) the dose measured
in milligrams per kilogram of body weight. The patients
were treated at weeks 0 (baseline), 2 and 6 and thereafter
at regular intervals (typically every 8 weeks). Arbitrarily pa-
tients were divided into three categories according to
dose per kilogram of body weight at the baseline visit:
43 , 35 , 55 mg/kg. Dose escalation was defined as
increased dose and/or reduced time intervals between
infusions compared with baseline.
Data quality
Queries were sent to the departments regarding treatment
series with incomplete data (infliximab dose regimens
and/or body weight) and the registries were corrected
accordingly.
Treatment duration
Treatment duration was the number of days individual pa-
tients maintained infliximab treatment. The start date was
the date the first dose was given and the stop date was
the date of the first missed dose. Temporary treatment
interruptions of43 months were allowed. All observations
were censored by 15 March 2013. Among patients with no
follow-up since 15 November 2012, data were censored
according to the last visit registered.
The reasons for drug discontinuation are registered in
DANBIO/ICEBIO in pre-specified categories: lack of treat-
ment effect (LOE), adverse events (AEs), disease remis-
sion, pregnancy, surgery, cancer, death, infections, loss
to follow-up and other reasons. In the following, reasons
for discontinuation are divided into three categories: AEs
(including infection, death or cancer), LOE and other
(including pregnancy, surgery, loss to follow-up, remission
or multiple reasons for discontinuation).
Treatment response
Disease activity and physical function were evaluated at
baseline and after 3, 6 and 12 months of therapy. The
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baseline visit was defined as the time window from 30
days before until 6 days after the initiation of therapy.
For the 3-month visit the time window was 1017
weeks, for the 6-month visit it was 1832 weeks and for
the 12-month visit it was 4664 weeks after initiation of
treatment. If more than one registration occurred within a
given time window, the one closest to the given time point
was selected for analysis. If a patient had no registrations
within a given time window, data were registered as miss-
ing for the given visit.
In the analyses of the 12-month outcome, the last ob-
servation carried forward (LOCF) method was used
among patients with missing data at the 12-month visit
and among patients who had stopped treatment within
the first year. All other calculations were based on
observed data with no imputation of missing data.
Clinical response was evaluated as achievement of
ACR 20%, 50% or 70% response (ACR20/50/70) [34] or
the European League Against Rheumatism (EULAR) good
response [35]. We classified patients as responders if they
achieved clinical response (yes/no) at both the 3 - and 6-
month visits compared with baseline. In case of missing
data at either the 3 - or 6-month visit, one registration of
clinical response was sufficient to characterize the patient
as a responder. Patients who had stopped treatment
within the first 10 weeks of therapy were considered
non-responders (non-responder imputation, n= 44).
Statistics
Statistical analyses were performed using SPSS version
16.0 (SPSS, Chicago, IL, USA) and SAS version 9.0 (SAS
Institute, Cary, NC, USA) software. Demographic and de-
scriptive data are presented as median [interquartile range
(IQR)]. Groups were compared by non-parametric tests
(chi-squared, MannWhitney, Wilcoxon signed rank test).
A P-value of< 0.05 was considered statistically
significant.
KaplanMeier plots and log-rank tests were performed
for infliximab drug survival analyses and to analyse time
until dose escalation. Univariate and multivariate Cox re-
gression analyses with hazard ratios (HRs) were used to
identify the impact of baseline infliximab dose on drug
survival. In the subanalysis of time to discontinuation
due to AEs, discontinuations due to ineffectiveness were
censored. Similarly, discontinuations due to AEs were
censored in the analysis of discontinuation due to ineffect-
iveness. Logistic regression analyses and odds ratios
were calculated to identify the impact of baseline inflixi-
mab dose on clinical response. Baseline infliximab dose
was included in all analyses as a categorical variable (43,
35, 55 mg/kg). Additional sensitivity analyses were per-
formed with the baseline dose (in mg/kg) as a continuous
variable.
All multivariate analyses were performed stratified by
country to avoid statistical interaction. The following base-
line variables were considered a priori confounders and
included in all multivariate analyses: gender, MTX use
(yes/no), patient age, time interval between infusions
(weeks), disease duration (years), HAQ and DAS28.
Calendar year of starting treatment and body weight
were considered intermediate variables potentially influ-
enced by the starting dose of infliximab and were not
included.
Results
A total of 462 infliximab-treated patients (376 Danish, 86
Icelandic) were included. Baseline demographics for
Danish and Icelandic patients are shown in Table 1 and
Table 2, respectively. The median starting infliximab dose
was 3.1 mg/kg (IQR 3.03.8) for Danish patients and
2.3 mg/kg (2.12.9) for Icelandic patients (P< 0.0001).
After up-titration, 94% of patients received infliximab at
8-week intervals. Danish patients had lower body weight
[80 kg (IQR 6894) vs 87 (7797), P= 0.001], lower BMI [27
kg/m2 (IQR 2430) vs 29 (2632), P= 0.001], higher DAS28
[4.7 (IQR 3.85.5) vs 4.2 (3.34.9), P= 0.009] and higher
tender joint count (TJC) [6 (IQR 211) vs 4 (26), P= 0.006]
compared with Icelandic patients upon initiation of ther-
apy, whereas other baseline characteristics [age, gender
distribution, height, disease duration, MTX use, VAS
score, swollen joint count (SJC) and CRP] were similar
(all P> 0.05).
At baseline, Danish patients treated with 55 mg/kg
infliximab had lower SJC and lower VAS physician score
compared with Danish patients on lower doses, whereas
other measures of disease activity were similar (Table 1).
Doses >5 mg/kg were more often started in the later years
and in women (Table 1). Among Icelandic patients there
was a tendency towards higher VAS physician score and
TJC among patients starting treatment with >3 mg/kg,
and no patients started on doses 55 mg/kg (Table 2). In
both Denmark and Iceland, patients with higher body
weight and BMI received lower doses per kilogram
(Table 1 and Table 2).
At 12 months median infliximab doses for Danish and
Icelandic patients were 3.3 mg/kg (IQR 3.04.5) and 2.9
(2.23.5) (P< 0.0001) every 8 (88) weeks, respectively.
The median dose per infusion was 300 mg (IQR
200300) and 200 (200300) (P< 0.01), respectively.
Danish patients had similar disease activity irrespective
of the baseline infliximab dose (LOCF, KruskalWallis
test; Table 3). Similar results were found in Icelandic pa-
tients (data not shown, all P> 0.05). There were no differ-
ences in DAS28, VAS score, SJC, TJC or HAQ after 12
months between Danish and Icelandic patients
(MannWhitney, all P> 0.05, data not shown).
At the latest registered visit, 247 patients (53%)
received infliximab in unaltered or reduced regimens,
whereas 145 patients (31%) (53% of Icelandic and 26%
of Danish patients) had an increased dose due to either
increased dose per infusion [65 patients, median dose
increase/kg 1.2 mg/kg (IQR 0.81.8)], shortening of the
time interval between infusions (32 patients) or both (48
patients). In 2% of patients the infliximab dose was
increased but the time intervals were prolonged or vice
versa. Data were missing in 13% of patients. Danish pa-
tients on increased infliximab dose regimens had longer
treatment duration [median 819 days (IQR 3211723)]
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compared with the patients receiving unaltered/reduced
doses [371 days (1591249)] (P< 0.001). Similar results
were found in Icelandic patients [1207 days (4322139)
vs 307 (120757), P< 0.001].
The numbers of Danish and Icelandic patients receiv-
ing starting doses of 43, 35 or 55 mg/kg are shown in
Fig. 1. Among patients with available data and who were
treated for >100 days, 77% (205/265) of Danish and 96%
(69/72) of Icelandic patients received sustained infliximab
doses <5 mg/kg (Fig. 1).
Data on baseline infliximab dose per kilogram were
missing in 71 Danish and 5 Icelandic patients. Danish pa-
tients with missing data had similar gender, BMI and age
distribution to the 305 patients with available data (all
P> 0.05), whereas patients with missing data more often
started treatment during earlier years (P< 0.0001). In
Icelandic patients, baseline demographics were similar
between patients with available and those with missing
data on baseline dose (all P> 0.05).
Cumulated follow-up time for Danish and Icelandic pa-
tients was 1185 patient-years and the median follow-up
time was 550 days (95% CI 383, 317). Overall, 116 pa-
tients (25%) stopped treatment due to LOE and 134 (29%)
stopped due to AEs. The reasons for stopping treatment
were similar for Danish and Icelandic patients (P= 0.4).
The starting infliximab dose per kilogram was similar be-
tween patients who continued treatment [median 3.0 mg/
kg (IQR 2.63.8)] and patients who stopped due to LOE
[3.1 mg/kg (2.73.6)] or AEs [3.1 mg/kg (2.93.5)] (P= 0.2).
At the latest visit, patients who stopped treatment due to
LOE received higher infliximab doses compared with pa-
tients who stopped due to AEs [median 3.5 mg/kg (IQR
3.04.7) vs 3.1 (2.93.7), P= 0.002].
After 12 months, 58% of Danish and 66% of Icelandic
patients were still on the drug. Drug survival was
significantly shorter among Danish compared with
Icelandic patients [median 483 days (95% CI 372, 594)
vs 1183 (4701896), log rank 7.7, P= 0.005] (Fig. 2A).
The starting infliximab dose did not affect survival
(Danish patients: Fig. 2B; Icelandic patients: Fig. 2C).
For Danish patients, drug survival was shorter in patients
not receiving concomitant MTX (Fig. 2D) and when treat-
ment was started in later years (Fig. 2E). Similar results
were found when KaplanMeier analyses were performed
among Icelandic patients (MTX use, P= 0.1; treatment
start year, P= 0.003). The start dose did not affect the
time until dose escalation (P= 0.9). The median number
of days until dose escalation was similar for Danish and
Icelandic patients [266 days (IQR 131560) vs 290
(182559), P= 0.2].
TABLE 1 Baseline demographics and disease activity for Danish patients registered in DANBIO according to infliximab
dose at the baseline visit
Total
Infliximab dose/kg (n=305 a)
P-valueb
43 mg 35 mg 5 5 mg
Patients, n 376 110 157 38
Infliximab dose, mg 290 (200300) 200 (200293) 300 (200300) 403 (400500) <0.0001
Female, n (%) 204 (54) 50 (45) 96 (61) 23 (61) 0.03
Dosing interval, weeks 8 (88) 8 (88) 8 (88) 8 (88) 0.04
Year starting TNFi, n (%)
20002 20 (5) 6 (5) 5 (3) 0 (0) <0.001
20035 104 (28) 30 (27) 31 (18) 6 (15)
20068 145 (39) 54 (49) 69 (44) 4 (11)
200912 107 (28) 20 (18) 52 (33) 28 (74)
Concomitant MTX, n (%) 260 (69) 82 (75) 111 22 0.2
Disease duration, years 7 (313) 9 (317) 7 (314) 6 (411) 0.6
Age, years 48 (4056) 46 (4055) 50 (4058) 47 (4154) 0.2
Body weight, kg 80 (6894) 82 (71100) 80 (6590) 80 (7090) 0.01
Body height, cm 172 (165178) 172 (166180) 172 (165178) 176 (167182) 0.2
BMI, kg/m2 27 (2430) 28 (2532) 26 (2330) 26 (2329) 0.006
HAQ 1.1 (0.81.6) 1.1 (0.61.6) 1.1 (0.81.6) 1.0 (0.61.8) 1.0
DAS28 4.7 (3.85.5) 4.9 (3.75.6) 4.7 (3.85.5) 4.0 (3.35.3) 0.1
CRP, mg/l 10 (425) 10 (524) 10 (426) 5 (212) 0.07
SJC, n (range) 2 (16) 3 (07) 2 (15) 1 (02) 0.02
TJC, n (range) 6 (211) 6 (214) 6 (211) 4 (19) 0.3
VAS physician, score (range) 37 (2355) 38 (2657) 39 (2252) 25 (1739) 0.02
VAS global, mm 69 (5184) 67 (5084) 68 (4987) 72 (5290) 0.9
VAS fatigue, mm 68 (4783) 69 (4577) 70 (4986) 68 (4290) 0.4
VAS pain, mm 62 (4376) 65 (4578) 62 (3775) 58 (3481) 0.8
Data are presented as median (interquartile range) unless stated otherwise. aMissing data on baseline infliximab dose in 71
patients. bP-value in KruskalWallis test. TNFi: TNF-a inhibitor; DAS28: 28-joint DAS; SJC: swollen joint count; TJC: tender
joint count; VAS: visual analogue scale.
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In multivariate Cox regression analysis among
Danish patients, infliximab starting dose as a categorical
value did not affect drug survival (P= 0.5). In a similar
analysis with starting dose as a continuous variable,
patients on a lower dose had shorter drug survival
[HR 0.7/mg/kg (95% CI 0.55, 0.95), P= 0.02]. The same
pattern was observed when looking only at patients
who withdrew due to AEs [HR 0.7/mg/kg (95% CI
TABLE 2 Baseline demographics and disease activity for Icelandic patients registered in ICEBIO according to infliximab
dose at the baseline visit
Total
Infliximab dose/kg (n=81a)
P-valueb
43 mg 35 mg 55 mg
Patients, n 86 64 17 0
Infliximab dose, mg 200 (200200) 200 (200200) 200 (200350) — <0.0001
Female, n (%) 48 (56) 35 (54) 12 (71) — 0.2
Dosing interval, weeks 8 (88) 8 (88) 8 (88) — 1.0
Year starting TNFi, n (%) —
20002 5 (6) 5 (8) 0 (0) — 0.9
20035 15 (17) 10 (16) 2 (12) —
20068 25 (29) 16 (25) 8 (47) —
200912 41 (48) 33 (52) 7 (41) —
Concomitant MTX, n (%) 53 (61) 40 (63) 10 (59) — 0.8
Disease duration, years 8 (317) 7 (317) 7 (235) — 0.8
Age, years 48 (3654) 49 (3755) 43 (3562) — 0.8
Body weight, kg 87 (7797) 92 (8099) 65 (6186) — <0.001
Body height, cm 172 (166182) 174 (167182) 167 (162169) — 0.002
BMI, kg/m2 29 (2632) 30 (2733) 24 (2130) — 0.006
HAQ 0.8 (0.31.1) 0.8 (0.31.0) 1.4 (0.22.1) — 0.3
DAS28 4.2 (3.34.9) 4.2 (3.34.9) 4.8 (4.46.0) — 0.1
CRP, mg/l 8 (519) 9 (419) 9 (639) — 0.7
SJC, n (range) 3 (15) 3 (15) 5 (18) — 0.6
TJC, n (range) 4 (26) 4 (26) 6 (517) — 0.08
VAS physician, score (range) 55 (4267) 51 (4064) 72 (5689) — 0.05
VAS global, mm 35 (3781) 64 (3880) 89 (4797) — 0.1
VAS fatigue, mm 74 (4580) 72 (4980) 91 (47100) — 0.1
VAS pain, mm 65 (4281) 63 (4580) 88 (4797) — 0.2
Data are presented as median (interquartile range) unless stated otherwise. aMissing data on baseline infliximab dose in five
patients. bP-value in KruskalWallis test. TNFi: TNF-a inhibitor; DAS28: 28-joint DAS; SJC: swollen joint count; TJC: tender
joint count; VAS: visual analogue scale.
TABLE 3 Disease activity at the 1-year visit for Danish patients according to the baseline infliximab dose
Baseline infliximab dose/kga
P-value43mg 35mg 55mg
Number still treated after 12 months, n (%) 70 (64) 89 (57) 24 (63)
HAQ 0.8 (0.21.3) 0.6 (0.11.1) 0.9 (0.21.4) 0.8
DAS28 3.0 (2.33.9) 3.1 (2.14.2) 2.4 (2.14.1) 0.3
CRP, mg/l 5 (210) 5 (211) 4 (1.58.5) 0.4
SJC, n (range) 0 (03) 0 (02) 0 (01) 0.1
TJC, n (range) 1 (04) 2 (06) 0 (06) 0.5
VAS global, mm 33 (1362) 33 (1563) 37 (1984) 0.9
VAS fatigue, mm 47 (1668) 50 (2576) 63 (2583) 0.6
VAS pain, mm 27 (1359) 32 (1056) 36 (1677) 0.2
Data are presented as median (interquartile range), unless stated otherwise. aMissing data on baseline dose, n= 39 (16%).
Last observation carried forward (LOCF) method. DAS28: 28-joint DAS; VAS: visual analogue scale; SJC: swollen joint count;
TJC: tender joint count.
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0.4, 1.1), P= 0.06] or LOE [HR 0.7 (95% CI 0.5, 1.0),
P= 0.07].
In multivariate Cox regression analysis of Icelandic pa-
tients, those who started treatment with doses43 mg/kg
had longer drug survival than patients starting on higher
doses [43 vs 35 mg/kg, HR 0.2 (95% CI 0.001, 0.5),
P= 0.02)]. In a similar analysis with infliximab starting
dose as a continuous variable, the starting dose was not
statistically significant (P= 0.6). Stratified analyses ac-
cording to the cause of treatment termination were not
performed in Icelandic patients due to few events.
In Danish patients, EULAR good response and ACR20/
50/70 response rates after 6 months were 33%, 38%,
23% and 10%, respectively. EULAR and ACR response
data were available in 54% and 63% of patients, respect-
ively, with no systematic differences between patients
with complete and incomplete data, except for more pa-
tients with missing ACR response data during earlier
years. The response rates were not associated with base-
line dose (as categorical or continuous variable) in either
univariate or multivariate analyses. In Icelandic patients,
EULAR good response and ACR20/50/70 response rates
after 6 months were 39%, 27%, 17% and 11%, respect-
ively. Response data were available in 38% of patients.
There were no statistically significant differences in
response rate between Danish and Icelandic patients
(all P> 0.05).
Discussion
In this observational study of 376 Danish and 86 Icelandic
patients with PsA treated with infliximab in routine care,
the majority of patients received continuous treatment
with doses below the 5 mg/kg recommended in interna-
tional guidelines. The starting infliximab dose did not
affect the time until dose increase, drug effectiveness or
drug survival. Icelandic patients received lower doses
than Danish patients but had similar response rates and
longer drug survival.
In RA, treatment with infliximab doses at 3 mg/kg with
gradual dose escalation according to clinical response is a
well-known treatment strategy [3638]. The recom-
mended infliximab dose regimen in PsA is 5 mg/kg every
8 weeks [13, 16] based on data from randomized con-
trolled trials (RCTs) [4, 6, 17, 18]. Few data are available
on the effectiveness of lower doses [39] and originate
mainly from small observational studies of 410 patients
[19, 21] or case reports [20]. No randomized trials on dose
escalation have been performed.
Infliximab starting doses in patients with PsA treated in
routine care vary across countries [4042]. In Sweden,
patients with PsA routinely receive a starting dose of
3 mg/kg [43, 44]. In the current study, Danish patients
received a median starting dose of 3.1 mg/kg, which
was independent of baseline disease activity. The more
frequent use of a 5 mg/kg starting dose after year 2008
might reflect that RA dose regimens were copied in the
earlier years and that adherence to international guide-
lines for PsA [13, 16] was higher in the later years. In
Iceland, the treating physicians complied with national
Icelandic treatment guidelines with a median starting
dose of 2.3 mg/kg and no patients started treatment
with doses 55 mg/kg.
Despite dose escalation in 53% of Icelandic and 26% of
Danish patients, the majority of patients received sus-
tained treatment with doses <5 mg/kg. This is in contrast
to observational data on 32 patients with PsA followed for
2 years by the South Swedish Arthritis Treatment Group
(SSATG). In the Swedish study, 72% of the patients
needed dose escalation [23]. The SSATG has previously
reported the average infliximab dose among 114 patients
with PsA to be 5 mg/kg every 8 weeks after 6 months of
treatment [43]. The Swedish patients apparently had simi-
lar baseline disease activity and demographics as the
Danish and Icelandic populations [23]. The Swedish stu-
dies provide no data on infliximab response rates and
survival [23, 43], so we do not know whether the different
regimens affected outcome.
Drug survival may be perceived as a measure of treat-
ment effectiveness [45]. In Danish patients, drug survival
was longer among patients who received higher baseline
infliximab doses, thus indicating a positive effect of higher
doses. However, the infliximab dose only affected drug
survival in multivariate and not univariate analyses. In
Icelandic patients, the picture was less clear, perhaps
due to limited statistical power. The different treatment
strategies in Denmark vs Iceland might have an impact
on the results. In Iceland, patients had lower disease
FIG. 1 Study flow chart of infliximab dose according to
treatment duration, stratified by country
6 www.rheumatology.oxfordjournals.org
Bente Glintborg et al.
 at Landspitalinn on Septem
ber 12, 2014
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
activity at treatment start and the majority of patients
received a fixed starting dose of 200 mg. In Denmark,
the starting dose was chosen according to the preference
of the treating physician. Thus confounding by indication
or channelling bias cannot be ruled out and differences in
disease severity, co-morbidities or other psoriatic disease
manifestations might have affected drug effectiveness as
judged by drug survival.
Observational and registry studies provide a valuable
supplement to RCTs regarding prescription practice and
treatment outcome when drugs are used in routine care
[29, 46]. In real life, with more liberal treatment criteria than
in RCTs, drug retention rates, and thus effectiveness, are
often lower. In addition, patients who stopped treatment
within 3 months were classified as non-responders in the
present study. As expected, we found the effectiveness of
infliximab in routine care to be lower than drug efficacy in
RCTs. Thus RCTs of infliximab in PsA have reported drug
efficacy (ACR20/50/70 response rates) to be approxi-
mately 50%, 35% and 20%, respectively [6, 47]. We did
not find effectiveness to be associated with the baseline
dose of infliximab. The current study demonstrated that
the clinical use of infliximab and adherence to national and
international guidelines varied between Denmark and
Iceland. This illustrates that extrapolation of outcome
data across countries must be done with caution and
that publication of clinical data from various countries is
of importance.
We found that concomitant MTX improved infliximab
drug survival. This is in accordance with previous studies
regarding TNFi treatment in PsA [25, 43, 4851]. The pos-
sible beneficial effect of MTX combination therapy in PsA
might be reduced formation of anti-chimeric antibodies
[23, 51, 52].
Drug survival was shorter among patients who started
treatment during the later years. This might illustrate a
change in prescription practice with initiation of TNFi
treatment among less ill patients with poorer treatment
outcomes [53]. Also, the availability of more TNFis might
lead to early switching [12]. This could also explain why
many patients stopped infliximab treatment due to LOE
although they only received a lower infliximab dose;
FIG. 2 KaplanMeier drug survival curves
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alternatively, economic considerations or fear of AEs
might have affected this decision.
This study has limitations to consider. Few patients
started treatment with infliximab 55 mg/kg and a lack of
power to detect potential beneficial effects of higher
doses cannot be excluded. Similarly, the patients who
stopped treatment due to LOE while receiving doses
<5 mg/kg might have experienced an effect on higher
doses. Response data were only available in approxi-
mately half of the patients, and this might have affected
our results. Although ACR and EULAR responses were
originally developed to monitor treatment effect in RA,
they have been widely used in PsA [54, 55]. However,
these measures do not include data on all joints poten-
tially affected in PsA, e.g. hips, DIP joints of the hand or
ankles and joints of the feet. This may be of importance
when these response measures are used in a clinical set-
ting and may cause an underestimation of disease activity
[56]. This might perhaps explain the relatively low median
SJC upon initiation of infliximab therapy seen in the pre-
sent study. Spinal disease might affect the starting dose:
perhaps patients with symptoms of spinal disease more
frequently received higher doses in accordance with the
guidelines for AS. Furthermore, enthesitis, dactylitis or
other psoriatic disease manifestations are potential con-
founders, but we did not have data to investigate this. To
address these issues further, a future randomized clinical
trial comparing low vs traditional infliximab doses in PsA
would be of relevance. Preferably such a trial should in-
clude data on not only 68-joint disease activity, but also
skin and other psoriatic disease domains.
In conclusion, this observational study from two coun-
tries demonstrated that infliximab doses below the recom-
mended 5 mg/kg were widely used in PsA in routine care.
A low starting dose with subsequent step-up therapy
seemed an effective strategy. Concomitant use of MTX
was associated with improved drug survival.
Rheumatology key messages
. In Denmark and Iceland, infliximab doses< 5 mg/kg
are widely used in routine treatment of PsA.
. A low infliximab starting dose with subsequent step
up therapy seems effective in PsA.
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